Skip to Content
Merck
  • Age-dependent neonatal intracerebral hemorrhage in plasminogen activator inhibitor 1 knockout mice.

Age-dependent neonatal intracerebral hemorrhage in plasminogen activator inhibitor 1 knockout mice.

Journal of neuropathology and experimental neurology (2014-04-09)
Philippe Leroux, Priscilla L Omouendze, Vincent Roy, Nathalie Dourmap, Bruno J Gonzalez, Carole Brasse-Lagnel, Peter Carmeliet, Isabelle Leroux-Nicollet, Stéphane Marret
ABSTRACT

Intracerebral-intraventricular hemorrhages (ICH/IVH) in very preterm neonates are responsible for high mortality and subsequent disabilities. In humans, tissue plasminogen activator (t-PA) initiates fibrinolysis and activates endoluminal-endothelial receptors; dysfunction of the t-PA inhibitor (PAI-1) results in recurrent hemorrhages. We used PAI-1 knockout (PAI-1) mice to examine the role of t-PA in age-dependent intracranial hemorrhages as a possible model of preterm ICH/IVH. Intracortical injection of 2 μL of phosphate-buffered saline produced a small traumatic injury and a high rate of hemorrhage in PAI-1 pups at postnatal day 3 (P3) or P5, whereas it had no effect in wild-type neonates. This resulted in white matter and cortical lesions, ventricle enlargement, hyperlocomotion, and altered cortical levels of serotonin and dopamine in the adult PAI mice. N-methyl-D-aspartate receptor blockers, plasmin- and matrix metalloproteinases inhibitors reduced hemorrhage and tissue lesions. In contrast to P3 to P5, no significant hemorrhages were induced in P10 PAI-1 pups and there were no behavioral or neurochemical alterations in adulthood. These data suggest that microvascular immaturity up to P5 in mice is a determinant factor required for t-PA-dependent vascular rupture. Neonatal PAI-1 mice could be a useful ICH/IVH model for studying the ontogenic window of vascular immaturity and vascular protection against later neurodisabilities.

MATERIALS
Product Number
Brand
Product Description

Aprotinin for system suitability, European Pharmacopoeia (EP) Reference Standard
Aminocaproic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Aprotinin from bovine lung, BioUltra, 3-8 TIU/mg solid, ≥98% (SDS-PAGE)
Sigma-Aldrich
6-Aminohexanoic acid, ≥98.5% (NT)
Sigma-Aldrich
Aprotinin from bovine lung
Sigma-Aldrich
6-Aminocaproic acid, ≥99% (titration), powder
Sigma-Aldrich
6-Aminocaproic acid, BioUltra, ≥99%
Sigma-Aldrich
Aprotinin from bovine lung, saline solution, 3-7 TIU/mg protein
Sigma-Aldrich
Aprotinin from bovine lung, lyophilized powder, 3-8 TIU/mg solid, BioReagent, suitable for cell culture
Sigma-Aldrich
Aprotinin from bovine lung, lyophilized powder, 3-7 TIU/mg solid
Sigma-Aldrich
Aprotinin from bovine lung, lyophilized powder, 3-8 TIU/mg solid
Supelco
Aminocaproic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Aprotinin solution, BRP, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Aprotinin from bovine lung, lyophilized, ~80% (HPCE), crystalline (fine), white, ≥3500 U/mg